0001179110-15-003690.txt : 20150227 0001179110-15-003690.hdr.sgml : 20150227 20150227165405 ACCESSION NUMBER: 0001179110-15-003690 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150226 FILED AS OF DATE: 20150227 DATE AS OF CHANGE: 20150227 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: THOMAS FRANK E CENTRAL INDEX KEY: 0001242616 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 15660104 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 edgar.xml FORM 4 - X0306 4 2015-02-26 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001242616 THOMAS FRANK E 1100 WINTER STREET WALTHAM MA 02451 0 1 0 0 EVP, Chief Operating Officer Common Stock 2015-02-26 4 A 0 12500 A 133588 D Stock Option (Right to Buy) 49.46 2015-02-26 4 A 0 25000 A 2025-02-26 Common Stock 25000 25000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of RSUs pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (the "Plan") and will vest in three equal annual installments with the first installment vesting on February 26, 2016. Not applicable. Grant of stock option pursuant to the Plan. This option will vest and become exercisable over four years after the grant date as follows: (i) 25% on the first anniversary of the grant date and (ii) the balance vesting in equal quarterly installments over the next three years thereafter. Nancy R. Smith, attorney-in-fact 2015-02-27